Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06391892

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery (LIQUIPANC)

Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery

Sponsor: Elisabethinen Hospital

Conditions Circulating Tumor Cell Pancreatic Cancer Predictive Cancer Model

Interventions Neoadjuvant chemotherapy instead of upfront surgery Upfront surgery

Updated 3 times since 2024 Last updated: Apr 25, 2024 Started: Jan 11, 2024 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06391892, this PHASE3 trial focuses on Circulating Tumor Cell and Pancreatic Cancer and remains actively recruiting participants. Sponsored by Elisabethinen Hospital, it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elisabethinen Hospital
Medical University Innsbruck

Data source: Elisabethinen Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Linz, Austria